PROTHENA CORP PLC

Prothena insider buying spikes as CEO William Scully buys 125K shares amid market volatility, signaling confidence in its Alzheimer’s drug pipeline and potential upside.

PROTHENA’s insider confidence, strong social‑media buzz, and strategic antibody pipeline suggest a promising future in Alzheimer’s therapeutics, but investors must weigh current valuation risks and market dynamics.